PMID- 34706808
OWN - NLM
STAT- MEDLINE
DCOM- 20211029
LR  - 20211029
IS  - 1550-7033 (Print)
IS  - 1550-7033 (Linking)
VI  - 17
IP  - 10
DP  - 2021 Oct 1
TI  - Protective Effect of Ginsenoside Rb1 Nanoparticles Against Contrast-Induced 
      Nephropathy by Inhibiting High Mobility Group Box 1 Gene/Toll-Like Receptor 
      4/NF-kappaB Signaling Pathway.
PG  - 2085-2098
LID - 10.1166/jbn.2021.3163 [doi]
AB  - With the progress made in the widespread application of interventional radiology 
      procedures, there has been an increasing number of patients who suffer from 
      cardiovascular diseases and go through imaging and interventional treatment with 
      iodine contrast medium (ICM) year by year. In turn, there has been an increasing 
      amount of concern over acute kidney injury (AKI) brought about by ICM. As 
      evidenced by numerous studies, the initiation of inflammatory response plays a 
      critical role in the development of ICM-induced AKI. Correspondingly, the 
      strategy of targeting renal inflammatory response and cytokine release could 
      provide an effective solution to mitigating the ICM-induced AKI. Moreover, 
      Ginsenoside Rb1 (GRb1) constitutes one of the major active components of ginseng 
      and features a wide range of vital biological functions. Judging from the 
      research findings, GRb1 could impose antioxidant and anti-inflammatory effects on 
      cardiovascular diseases, in addition to lung, liver and kidney diseases. However, 
      reports on whether GRb1 could impose a protective effect against contrast-induced 
      nephropathy (CIN) are absent. In this study, we have examined the therapeutic 
      effects imposed by GRb1 as well as the potential molecular mechanism by 
      establishing an in vivo and in vitro model of CIN. In addition, we have set up a 
      mouse model of CIN through sequential intravenous injection of indomethacin, 
      N(omega)-nitro-Larginine methyl ester (L-NAME), and iopromide. To further enhance the 
      bioavailability of GRb1, we have encapsulated GRb1 with polyethylene glycol 
      (PEG)/poly lactic-co-glycolic acid (PLGA) nanocarriers to generate GRb1 
      nanoparticles (NPs) conducting the in vivo experiments. During the in vitro 
      experiments, we have adopted GRb1 to treat NRK-52E cells or cells transfected 
      with the high mobility group box 1 gene (HMGB1) overexpression plasmid. As shown 
      by the in vivo experimental results, GRb1 NPs could evidently improve the renal 
      dysfunction in CIN, diminish the extent of apoptosis of tubular epithelial cells, 
      and reduce the expression of high mobility group box 1 (HMGB1) and cytokines 
      (tumor necrosis factor (TNF-alpha), interleukin (IL) 6 and IL-1beta). In addition, GRb1 
      NPs are found to be capable of preventing the activation of Toll-like receptor 4 
      (TLR4)/NF-kappaB signaling pathway triggered by contrast medium. The in vitro 
      experimental results have exactly confirmed the findings of the in vivo 
      experiments. In the meantime, through the observation of the in vitro assays, 
      overexpression of HMGB1 can partially counteract the beneficial effects imposed 
      by GRb1. Judging from our research data, GRb1 could impose a protective effect 
      against CIN by inhibiting inflammatory response via HMGB1/TLR4/NF-kappaB pathway, 
      whereas HMGB1 constitutes a critical molecular target of GRb1.
FAU - Zhou, Shuai
AU  - Zhou S
AD  - Cardiology Department, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, 450000, PR China.
FAU - Lu, Shan
AU  - Lu S
AD  - Emergency Department, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, 450000, PR China.
FAU - Guo, Sen
AU  - Guo S
AD  - Cardiology Department, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, 450000, PR China.
FAU - Zhao, Luosha
AU  - Zhao L
AD  - Cardiology Department, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, 450000, PR China.
FAU - Han, Zhanying
AU  - Han Z
AD  - Cardiology Department, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, 450000, PR China.
FAU - Li, Zhenzhen
AU  - Li Z
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Biomed Nanotechnol
JT  - Journal of biomedical nanotechnology
JID - 101230869
RN  - 0 (Ginsenosides)
RN  - 0 (NF-kappa B)
RN  - 0 (RB1 protein, human)
RN  - 0 (Retinoblastoma Binding Proteins)
RN  - 0 (Toll-Like Receptor 4)
RN  - 7413S0WMH6 (ginsenoside Rb1)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
SB  - IM
MH  - Animals
MH  - Ginsenosides
MH  - Humans
MH  - *Kidney Diseases
MH  - Mice
MH  - NF-kappa B/genetics/metabolism
MH  - *Nanoparticles/toxicity
MH  - Retinoblastoma Binding Proteins
MH  - Signal Transduction
MH  - Toll-Like Receptor 4/metabolism
MH  - Ubiquitin-Protein Ligases
EDAT- 2021/10/29 06:00
MHDA- 2021/10/30 06:00
CRDT- 2021/10/28 05:35
PHST- 2021/10/28 05:35 [entrez]
PHST- 2021/10/29 06:00 [pubmed]
PHST- 2021/10/30 06:00 [medline]
AID - 10.1166/jbn.2021.3163 [doi]
PST - ppublish
SO  - J Biomed Nanotechnol. 2021 Oct 1;17(10):2085-2098. doi: 10.1166/jbn.2021.3163.